Prednisone

Generic Name: Prednisone

Brand Names: Deltasone, Rayos, Winpred

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆O_₅

CAS Number: 53-03-2

Unique Ingredient Identifier: VB0R961HZT

Background: A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication: Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions: Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

Phase 2

Active, not recruiting

Conditions: Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
High Grade B-Cell Lymphoma, Not Otherwise Specified
Indolent Non-Hodgkin Lymphoma
Mediastinal B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
Aggressive Non-Hodgkin Lymphoma
Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Drug: Etoposide
Biological: Nivolumab
Drug: Prednisone
Biological: Rituximab
Drug: Vincristine Sulfate

First Posted Date: 2018-11-21

Last Posted Date: 2024-11-04

Lead Sponsor: David Bond, MD

Target Recruit Count: 30

Registration Number: NCT03749018

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer

Phase 3

Active, not recruiting

Conditions: Castration-Resistant Prostatic Cancer

Interventions: Drug: Niraparib
Drug: Abiraterone Acetate
Drug: New Formulation of Niraparib and Abiraterone Acetate (AA)
Drug: Prednisone
Drug: Placebo

First Posted Date: 2018-11-21

Last Posted Date: 2024-12-09

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 765

Registration Number: NCT03748641

Locations: 🇺🇸
Massachusetts General, Boston, Massachusetts, United States
🇺🇸
VA Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸
Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States

and more 316 locations

Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma

Phase 1

Conditions: Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma Activated B-Cell Type
High Grade B-Cell Lymphoma, Not Otherwise Specified
Diffuse Large B-Cell Lymphoma
High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements

Interventions: Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Drug: Prednisone
Biological: Rituximab
Drug: Spleen Tyrosine Kinase Inhibitor TAK-659
Drug: Vincristine Sulfate

First Posted Date: 2018-11-15

Last Posted Date: 2021-05-06

Lead Sponsor: Northwestern University

Target Recruit Count: 12

Registration Number: NCT03742258

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States

Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years

Phase 3

Active, not recruiting

Conditions: Newly Diagnosed Multiple Myeloma

Interventions: Drug: Lenalidomide.
Drug: Bortezomib
Drug: Carfilzomib
Drug: Dexamethasone
Drug: Daratumumab
Drug: Prednisone
Drug: Melphalan

First Posted Date: 2018-11-15

Last Posted Date: 2022-09-14

Lead Sponsor: PETHEMA Foundation

Target Recruit Count: 462

Registration Number: NCT03742297

Locations: 🇪🇸
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
🇪🇸
Hospital Universitario de Cruces, Bilbao, Spain
🇪🇸
Complejo Hospitalario Regional Reina Sofía, Córdoba, Spain

and more 55 locations

Tocilizumab Plus a Short Prednisone Taper for GCA

Phase 4

Completed

Conditions: Giant Cell Arteritis

Interventions: Drug: Tocilizumab
Drug: Prednisone

First Posted Date: 2018-10-31

Last Posted Date: 2022-12-02

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 30

Registration Number: NCT03726749

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma

Early Phase 1

Recruiting

Conditions: NK-Cell Leukemia
Peripheral T Cell Lymphoma
NK-Cell Lymphoma

Interventions: Drug: pralatraxate,
Drug: Methotrexate
Drug: Ifosfamide
Drug: cyclophosphamide
Drug: Dexamethasone
Drug: Doxorubicin
Drug: Etoposide
Drug: Prednisone
Drug: calaspargase pegol
Drug: Brentuximab Vedotin

First Posted Date: 2018-10-25

Last Posted Date: 2023-10-26

Lead Sponsor: New York Medical College

Target Recruit Count: 40

Registration Number: NCT03719105

Locations: 🇺🇸
Children's Hospital Orange County, Orange, California, United States
🇺🇸
Helen De Vos, Grand Rapids, Michigan, United States
🇺🇸
University of Alabama, Birmingham, Alabama, United States

and more 3 locations

Leflunomide Treatment for IgG4-RD

Not Applicable

Conditions: Autoimmune Disease

Interventions: Drug: Prednisone
Drug: Prednisone and Leflunomide

First Posted Date: 2018-10-23

Last Posted Date: 2018-10-23

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 70

Registration Number: NCT03715699

Locations: 🇨🇳
Yunyun Fei, Beijing, Beijing, China

A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer

Phase 2

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Drug: Abemaciclib
Drug: Abiraterone Acetate
Drug: Prednisone
Drug: Placebo

First Posted Date: 2018-10-16

Last Posted Date: 2024-10-18

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 350

Registration Number: NCT03706365

Locations: 🇺🇸
St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
🇺🇸
Mayo Clinic in Arizona - Phoenix, Phoenix, Arizona, United States
🇺🇸
The University of Arizona Cancer Center - North Campus, Tucson, Arizona, United States

and more 107 locations

Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma

Phase 1

Suspended

Conditions: Diffuse Large B-Cell Lymphoma Unclassifiable
Intravascular Large B-Cell Lymphoma
Primary Mediastinal (Thymic) Large B-Cell Lymphoma
T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
CD20 Positive
B-Cell Non-Hodgkin Lymphoma
Aggressive Non-Hodgkin Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Biological: Nivolumab
Drug: Prednisone
Other: Quality-of-Life Assessment
Biological: Rituximab
Drug: Vincristine Sulfate

First Posted Date: 2018-10-15

Last Posted Date: 2022-08-15

Lead Sponsor: Northwestern University

Target Recruit Count: 30

Registration Number: NCT03704714

Locations: 🇺🇸
Northwestern University- Lake Forest Hospital, Lake Forest, Illinois, United States
🇺🇸
Northwestern Medicine: Delnor, DuPage, Warrenville, Kishwaukee (West Region), Warrenville, Illinois, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States

and more 1 locations

The Effect of Some Drugs Used in Treatment of Vasculitis on the Complement System in Children

Phase 3

Conditions: Vasculitis

Interventions: Drug: Ibuprofen
Drug: Prednisone
Drug: Methotrexate

First Posted Date: 2018-10-02

Last Posted Date: 2021-02-15

Lead Sponsor: Assiut University

Target Recruit Count: 70

Registration Number: NCT03692416

Locations: 🇪🇬
Assiut University Pediatric Hospital, Assiut, Upper Egypt, Egypt

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy